GT201700033A - Anticuerpos anti tigit - Google Patents
Anticuerpos anti tigitInfo
- Publication number
- GT201700033A GT201700033A GT201700033A GT201700033A GT201700033A GT 201700033 A GT201700033 A GT 201700033A GT 201700033 A GT201700033 A GT 201700033A GT 201700033 A GT201700033 A GT 201700033A GT 201700033 A GT201700033 A GT 201700033A
- Authority
- GT
- Guatemala
- Prior art keywords
- tigit antibodies
- anti tigit
- antibodies
- cancer
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS ANTI TIGIT, ASÍ COMO AL USO DE ESTOS ANTICUERPOS EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO CÁNCER Y ENFERMEDAD INFECCIOSA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462038912P | 2014-08-19 | 2014-08-19 | |
US201562126733P | 2015-03-02 | 2015-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201700033A true GT201700033A (es) | 2019-09-30 |
Family
ID=53938463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201700033A GT201700033A (es) | 2014-08-19 | 2017-02-17 | Anticuerpos anti tigit |
Country Status (31)
Country | Link |
---|---|
US (4) | US20160355589A1 (es) |
EP (1) | EP3183267A1 (es) |
JP (3) | JP6920194B2 (es) |
KR (2) | KR102050082B1 (es) |
CN (2) | CN107148430B (es) |
AP (1) | AP2017009765A0 (es) |
AU (3) | AU2015305754B2 (es) |
BR (1) | BR112017003108A8 (es) |
CA (1) | CA2957722C (es) |
CL (2) | CL2017000310A1 (es) |
CO (1) | CO2017001561A2 (es) |
CR (1) | CR20170060A (es) |
DO (1) | DOP2017000046A (es) |
EA (1) | EA036311B1 (es) |
GE (1) | GEP20217331B (es) |
GT (1) | GT201700033A (es) |
IL (1) | IL250583B (es) |
JO (2) | JO3664B1 (es) |
MA (1) | MA40475A (es) |
MD (1) | MD4733C1 (es) |
MX (2) | MX2017002229A (es) |
MY (2) | MY184288A (es) |
NI (1) | NI201700019A (es) |
PE (1) | PE20170289A1 (es) |
PH (1) | PH12017500296A1 (es) |
SG (1) | SG11201701161QA (es) |
TN (1) | TN2017000024A1 (es) |
TW (2) | TWI724997B (es) |
UA (1) | UA122395C2 (es) |
WO (1) | WO2016028656A1 (es) |
ZA (1) | ZA201700955B (es) |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
SG10201402815VA (en) | 2008-04-09 | 2014-09-26 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
RS59480B1 (sr) | 2013-12-12 | 2019-12-31 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
MA47849A (fr) | 2014-05-28 | 2020-01-29 | Agenus Inc | Anticorps anti-gitr et leurs procédés d'utilisation |
IL250583B (en) | 2014-08-19 | 2022-07-01 | Merck Sharp & Dohme | Anti-tigit antibodies |
TWI708786B (zh) | 2014-12-23 | 2020-11-01 | 美商必治妥美雅史谷比公司 | 針對tigit之抗體 |
US10550173B2 (en) | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
CN107580500B (zh) | 2015-02-19 | 2023-05-30 | 康姆普根有限公司 | 抗pvrig抗体和使用方法 |
SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
US10766957B2 (en) | 2015-08-14 | 2020-09-08 | Merck Sharp & Dohme Corp | Anti-TIGIT antibodies |
EA201890630A1 (ru) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | Антитела против pd-1 и способы их применения |
ES2924071T3 (es) | 2015-09-02 | 2022-10-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT) |
EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
CN108368176B (zh) | 2015-10-01 | 2022-06-07 | 波滕扎治疗公司 | 抗tigit抗原结合蛋白及其使用方法 |
IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
WO2017152088A1 (en) * | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
WO2017165681A1 (en) | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
MX2018014387A (es) | 2016-05-27 | 2019-03-14 | Agenus Inc | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos. |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
TWI784957B (zh) | 2016-06-20 | 2022-12-01 | 英商克馬伯有限公司 | 免疫細胞介素 |
US11858996B2 (en) | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
EP3617232A1 (en) * | 2016-08-17 | 2020-03-04 | Compugen Ltd. | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
TW202246349A (zh) | 2016-10-11 | 2022-12-01 | 美商艾吉納斯公司 | 抗lag-3抗體及其使用方法 |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
CA3042698A1 (en) | 2016-11-04 | 2018-05-11 | Aximmune, Inc. | Beta-alethine, immune modulators, and uses thereof |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
EP3548071A4 (en) | 2016-11-30 | 2020-07-15 | OncoMed Pharmaceuticals, Inc. | METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES |
WO2018102746A1 (en) * | 2016-12-02 | 2018-06-07 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to tigit |
US10232053B2 (en) | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
EP3565839A4 (en) | 2017-01-05 | 2021-04-21 | Gensun Biopharma Inc. | CHECKPOINT REGULATOR ANTAGONISTS |
KR20190124753A (ko) * | 2017-03-03 | 2019-11-05 | 리나트 뉴로사이언스 코프. | 항-gitr 항체 및 이의 사용 방법 |
JOP20190203A1 (ar) * | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
WO2018187191A1 (en) | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
EP4286009A3 (en) | 2017-04-21 | 2024-04-03 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
KR20190141223A (ko) | 2017-04-26 | 2019-12-23 | 브리스톨-마이어스 스큅 컴퍼니 | 디술피드 결합 환원을 최소화하는 항체 생산 방법 |
EP3618863B1 (en) | 2017-05-01 | 2023-07-26 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
RU2019138519A (ru) * | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Стабильные составы антител против tigit, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
US11225523B2 (en) | 2017-06-01 | 2022-01-18 | Compugen Ltd. | Triple combination antibody therapies |
WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
US20200407445A1 (en) * | 2017-07-27 | 2020-12-31 | Iteos Therapeutics Sa | Anti-tigit antibodies |
BE1025333B1 (fr) * | 2017-07-27 | 2019-01-23 | Iteos Therapeutics S.A. | Anticorps anti-tigit |
WO2019023504A1 (en) | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | ANTI-TIGIT ANTIBODIES |
TWI803523B (zh) * | 2017-09-29 | 2023-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Tigit抗體、其抗原結合片段及醫藥用途 |
EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
KR20200104333A (ko) * | 2017-12-28 | 2020-09-03 | 난징 레전드 바이오테크 씨오., 엘티디. | Tigit에 대한 단일-도메인 항체 및 이의 변이체 |
TW202400654A (zh) * | 2017-12-30 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
US11708410B2 (en) | 2018-01-15 | 2023-07-25 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against TIGIT |
WO2019152574A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
KR102224556B1 (ko) * | 2018-02-06 | 2021-03-09 | 아이-맵 바이오파마 유에스 리미티드 | Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용 |
MX2020008795A (es) * | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti cuerpos anti tigit y usos de los mismos. |
WO2019191133A1 (en) | 2018-03-27 | 2019-10-03 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
AR114789A1 (es) * | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
US20210130459A1 (en) | 2018-05-09 | 2021-05-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human nectin4 |
WO2019232484A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
WO2020006511A1 (en) | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Trispecific antagonists |
SG11202100746WA (en) * | 2018-07-25 | 2021-03-30 | Innovent Biologics Suzhou Co Ltd | Anti-tigit antibody and use thereof |
US11401339B2 (en) | 2018-08-23 | 2022-08-02 | Seagen Inc. | Anti-TIGIT antibodies |
JP7397874B2 (ja) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
CN110511912B (zh) * | 2018-08-30 | 2024-03-22 | 浙江煦顼技术有限公司 | 免疫细胞的功能调节 |
AU2019328575A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
JP2022512851A (ja) * | 2018-11-05 | 2022-02-07 | メルク・シャープ・アンド・ドーム・コーポレーション | がんの処置のための抗tigit抗体の投薬レジメン |
CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
MX2021008216A (es) | 2019-01-07 | 2021-11-04 | iTeos Belgium SA | Anticuerpos anti-tigit. |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
EP3938396A1 (en) | 2019-03-11 | 2022-01-19 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
CN111744013B (zh) * | 2019-03-29 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 |
CN111744007B (zh) * | 2019-03-29 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 一种抗tigit抗体药物组合物及其用途 |
KR20220012292A (ko) | 2019-05-23 | 2022-02-03 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 배양 배지를 모니터링하는 방법 |
TWI760751B (zh) | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
MX2021013850A (es) * | 2019-06-13 | 2022-01-07 | Green Cross Corp | Anticuerpo contra tigit y uso del mismo. |
US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
US10851157B2 (en) | 2019-07-01 | 2020-12-01 | Gensun Biopharma, Inc. | Antagonists targeting the TGF-β pathway |
WO2021008523A1 (zh) * | 2019-07-15 | 2021-01-21 | 上海君实生物医药科技股份有限公司 | 抗tigit抗体及其应用 |
WO2021021767A1 (en) * | 2019-07-30 | 2021-02-04 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bispecific antibodies |
EP3798235A1 (en) * | 2019-09-24 | 2021-03-31 | Industrial Technology Research Institute | Anti-tigit antibodies and methods of use |
TW202128755A (zh) * | 2019-09-27 | 2021-08-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 抗原結合蛋白 |
US20220340660A1 (en) * | 2019-10-01 | 2022-10-27 | Merck Sharp & Dohme Corp. | Biomarkers for anti-tigit antibody treatment |
AU2020378335A1 (en) | 2019-11-05 | 2022-04-07 | Merck Patent Gmbh | Anti-TIGIT antibodies and uses thereof |
JP2022554270A (ja) | 2019-11-05 | 2022-12-28 | ジョンス セラピューティクス, インコーポレイテッド | 抗pd-1抗体による癌を治療する方法 |
CN114641502B (zh) * | 2019-11-14 | 2023-11-14 | 上海药明生物技术有限公司 | 一种新的抗tigit抗体 |
WO2021113831A1 (en) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | 包含il-7變體之雙官能分子 |
BR112022012918A2 (pt) | 2020-01-07 | 2022-09-06 | Univ Texas | Variantes de enzima de exaustão de metiltioadenosina/adenosina humana melhorada para terapia do câncer |
IL295084A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Chromatography resin and its uses |
IL295077A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Methods for treating age-related and inflammatory diseases |
IL295083A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Methods for activating regulatory t cells |
US20240043530A1 (en) | 2020-03-13 | 2024-02-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PVRIG Binding Protein And Its Medical Uses |
CN115916247A (zh) * | 2020-04-19 | 2023-04-04 | 奥美药业有限公司 | 人tigit特异性单域抗体及其应用 |
CN113563470B (zh) | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
CN115943312A (zh) | 2020-05-07 | 2023-04-07 | 法国居里学院 | 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途 |
CN114507284B (zh) * | 2020-05-09 | 2023-05-26 | 华博生物医药技术(上海)有限公司 | 抗tigit的抗体、其制备方法和应用 |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
JP2023527869A (ja) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
MX2022015157A (es) | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
EP4168118A1 (en) | 2020-06-18 | 2023-04-26 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
WO2021258337A1 (en) * | 2020-06-24 | 2021-12-30 | Huahui Health Ltd. | Human monoclonal antibodies against tigit for immune related diseases |
CN111718415B (zh) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | 一种抗tigit纳米抗体及其应用 |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
WO2022044010A1 (en) | 2020-08-26 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections |
CN116406369A (zh) | 2020-10-05 | 2023-07-07 | 百时美施贵宝公司 | 用于浓缩蛋白质的方法 |
TW202233248A (zh) | 2020-11-08 | 2022-09-01 | 美商西健公司 | 組合療法 |
US11028172B1 (en) * | 2020-11-10 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Anti-TIGIT antibodies and uses thereof |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
WO2022111612A1 (zh) * | 2020-11-26 | 2022-06-02 | 信达生物制药(苏州)有限公司 | 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途 |
WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
KR20220082776A (ko) * | 2020-12-10 | 2022-06-17 | 주식회사 유틸렉스 | 항-tigit 항체 및 이의 용도 |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
US11806507B2 (en) * | 2020-12-22 | 2023-11-07 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
US20240050646A1 (en) * | 2020-12-22 | 2024-02-15 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
US20220193235A1 (en) * | 2020-12-22 | 2022-06-23 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion |
WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
EP4293045A1 (en) | 2021-01-14 | 2023-12-20 | Shanghai Junshi Biosciences Co., Ltd. | Anti-tigit antibody pharmaceutical composition and application thereof |
WO2022184068A1 (zh) * | 2021-03-02 | 2022-09-09 | 百奥泰生物制药股份有限公司 | 抗tigit抗体在治疗肿瘤或癌症中的应用 |
CN114984227A (zh) * | 2021-03-02 | 2022-09-02 | 百奥泰生物制药股份有限公司 | 抗tigit抗体在联合用药中的应用 |
WO2022217026A1 (en) | 2021-04-09 | 2022-10-13 | Seagen Inc. | Methods of treating cancer with anti-tigit antibodies |
IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | A new scaffold for bifunctional molecules with improved properties |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
EP4339208A1 (en) * | 2021-05-10 | 2024-03-20 | MediMabbio Inc. | Anti-tigit antibodies and use thereof |
CN115368457A (zh) * | 2021-05-18 | 2022-11-22 | 苏州鑫康合生物医药科技有限公司 | 抗tigit抗体及其用途 |
CN115466327A (zh) * | 2021-06-10 | 2022-12-13 | 北京天广实生物技术股份有限公司 | 结合tigit的抗体及其用途 |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
WO2023036340A1 (en) * | 2021-09-13 | 2023-03-16 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Protein complexes targeting il21 pathway |
CN117858903A (zh) | 2021-09-15 | 2024-04-09 | 江苏恒瑞医药股份有限公司 | 一种含抗pvrig/tigit双特异性抗体的药物组合物 |
TW202328195A (zh) | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合pd-1的蛋白及其醫藥用途 |
CN115838424A (zh) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | 靶向tigit的单克隆抗体 |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023239226A1 (ko) * | 2022-06-10 | 2023-12-14 | 메디맵바이오 주식회사 | Tigit에 특이적으로 결합하는 항체 및 인터류킨-15를 포함하는 융합 단백질 및 이의 용도 |
KR20230171885A (ko) * | 2022-06-10 | 2023-12-21 | 메디맵바이오 주식회사 | 항-tigit 항체, 인터류킨-15, 및 인터류킨-15 수용체 알파 스시 도메인을 포함하는 융합 단백질 및 이의 용도 |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
MXPA01005515A (es) | 1998-12-01 | 2003-07-14 | Protein Design Labs Inc | Anticuerpos humanizados para gamma-interferon. |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US7368527B2 (en) | 1999-03-12 | 2008-05-06 | Human Genome Sciences, Inc. | HADDE71 polypeptides |
EP1173462A1 (en) | 1999-03-26 | 2002-01-23 | Human Genome Sciences, Inc. | 50 human secreted proteins |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING A POLYPEPTIDE |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
KR100787073B1 (ko) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | 변형된 당단백질의 제조방법 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
JP5401001B2 (ja) | 2002-09-11 | 2014-01-29 | ジェネンテック, インコーポレイテッド | 免疫関連疾患の治療のための新規組成物と方法 |
AU2003267097B2 (en) | 2002-09-11 | 2009-09-17 | Genentech, Inc. | Novel composition and methods for the treatment of psoriasis |
EP1551876B1 (en) | 2002-10-16 | 2011-03-16 | Purdue Pharma L.P. | Antibodies that bind cell-associated ca 125/0722p and methods of use thereof |
US20090047213A1 (en) * | 2003-04-14 | 2009-02-19 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
AU2005269759A1 (en) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
CN101023102B (zh) * | 2004-09-17 | 2013-05-29 | 霍夫曼-拉罗奇有限公司 | 抗-ox40l抗体 |
WO2006124667A2 (en) | 2005-05-12 | 2006-11-23 | Zymogenetics, Inc. | Compositions and methods for modulating immune responses |
MX2008000253A (es) | 2005-07-08 | 2008-04-02 | Biogen Idec Inc | Anticuerpos de sp35 y usos de los mismos. |
CN101589058A (zh) * | 2006-10-20 | 2009-11-25 | 株式会社未来创药研究所 | 包含抗hb-egf抗体作为活性成分的癌症治疗剂 |
MX2009005189A (es) * | 2006-11-15 | 2009-06-30 | Medarex Inc | Anticuerpos humanos monoclonales para btla y metodos de uso. |
NZ593450A (en) * | 2007-02-02 | 2012-08-31 | Baylor Res Inst | Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells |
CA2678749C (en) * | 2007-02-23 | 2018-03-13 | Schering Corporation | Engineered anti-il-23p19 antibodies |
CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
SG10201402815VA (en) | 2008-04-09 | 2014-09-26 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
AU2015202123B2 (en) | 2008-04-09 | 2017-06-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
EP2462161B1 (en) | 2009-08-06 | 2017-03-08 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
CA2775573A1 (en) | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
CA2783107C (en) | 2009-12-05 | 2018-08-07 | Ann-Kristin Mueller | Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins |
BR112012026227A2 (pt) * | 2010-04-13 | 2020-08-04 | Celldex Therapeutics, Inc. | anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo |
EP2580238A1 (en) | 2010-06-09 | 2013-04-17 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
NZ629913A (en) | 2010-08-23 | 2016-01-29 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
US9205144B2 (en) | 2011-06-03 | 2015-12-08 | Dana-Farber Cancer Institute, Inc. | Identification of conserved peptide blocks in homologous polypeptides |
KR20130062168A (ko) | 2011-12-02 | 2013-06-12 | 고려대학교 산학협력단 | 재조합 형광 단백질 나노입자 |
NZ629178A (en) | 2012-02-29 | 2016-09-30 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
WO2013148316A1 (en) | 2012-03-29 | 2013-10-03 | Biogen Idec Ma Inc. | Biomarkers for use in integrin therapy applications |
WO2013151999A1 (en) | 2012-04-02 | 2013-10-10 | President And Fellows Of Harvard College | Cancer treatment and immune system regulation through fat10 pathway inhibition |
CA2875980A1 (en) | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
RS58528B1 (sr) | 2012-12-03 | 2019-04-30 | Bristol Myers Squibb Co | Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina |
AR093788A1 (es) * | 2012-12-04 | 2015-06-24 | Oncomed Pharm Inc | Inmunoterapia con agentes de enlace |
CN103073644B (zh) * | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
US20140314741A1 (en) | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
KR20160030936A (ko) | 2013-07-16 | 2016-03-21 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법 |
RU2016137264A (ru) | 2014-02-21 | 2018-03-26 | МЕДИММЬЮН, ЭлЭлСи | Слияния антитела к pcsk9~glp-1 и способы применения |
WO2016011264A1 (en) | 2014-07-16 | 2016-01-21 | Genentech, Inc. | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
IL250583B (en) | 2014-08-19 | 2022-07-01 | Merck Sharp & Dohme | Anti-tigit antibodies |
RU2017119428A (ru) | 2014-11-06 | 2018-12-06 | Дженентек, Инк. | Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit |
EP3221346B1 (en) | 2014-11-21 | 2020-09-02 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
TWI708786B (zh) | 2014-12-23 | 2020-11-01 | 美商必治妥美雅史谷比公司 | 針對tigit之抗體 |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
CR20220186A (es) | 2015-09-25 | 2022-07-07 | Genentech Inc | ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225) |
-
2015
- 2015-08-17 IL IL250583A patent/IL250583B/en unknown
- 2015-08-17 TN TN2017000024A patent/TN2017000024A1/en unknown
- 2015-08-17 GE GEAP201514450A patent/GEP20217331B/en unknown
- 2015-08-17 CN CN201580056517.5A patent/CN107148430B/zh active Active
- 2015-08-17 WO PCT/US2015/045447 patent/WO2016028656A1/en active Application Filing
- 2015-08-17 TW TW104126739A patent/TWI724997B/zh active
- 2015-08-17 MX MX2017002229A patent/MX2017002229A/es unknown
- 2015-08-17 MY MYPI2017000221A patent/MY184288A/en unknown
- 2015-08-17 CR CR20170060A patent/CR20170060A/es unknown
- 2015-08-17 JO JOP/2015/0195A patent/JO3664B1/ar active
- 2015-08-17 MY MYPI2020006588A patent/MY198017A/en unknown
- 2015-08-17 PE PE2017000229A patent/PE20170289A1/es unknown
- 2015-08-17 KR KR1020177007124A patent/KR102050082B1/ko active IP Right Grant
- 2015-08-17 US US15/121,624 patent/US20160355589A1/en not_active Abandoned
- 2015-08-17 EA EA201790413A patent/EA036311B1/ru not_active IP Right Cessation
- 2015-08-17 SG SG11201701161QA patent/SG11201701161QA/en unknown
- 2015-08-17 BR BR112017003108A patent/BR112017003108A8/pt active Search and Examination
- 2015-08-17 AU AU2015305754A patent/AU2015305754B2/en active Active
- 2015-08-17 KR KR1020197034657A patent/KR102321168B1/ko active IP Right Grant
- 2015-08-17 UA UAA201702456A patent/UA122395C2/uk unknown
- 2015-08-17 CA CA2957722A patent/CA2957722C/en active Active
- 2015-08-17 EP EP15753872.9A patent/EP3183267A1/en active Pending
- 2015-08-17 JP JP2017509009A patent/JP6920194B2/ja active Active
- 2015-08-17 TW TW110113123A patent/TWI790593B/zh active
- 2015-08-17 AP AP2017009765A patent/AP2017009765A0/en unknown
- 2015-08-17 CN CN202110901846.2A patent/CN113583131A/zh active Pending
- 2015-08-17 MD MDA20170032A patent/MD4733C1/ro active IP Right Grant
- 2015-08-17 MA MA040475A patent/MA40475A/fr unknown
-
2017
- 2017-02-07 ZA ZA2017/00955A patent/ZA201700955B/en unknown
- 2017-02-07 CL CL2017000310A patent/CL2017000310A1/es unknown
- 2017-02-16 PH PH12017500296A patent/PH12017500296A1/en unknown
- 2017-02-17 NI NI201700019A patent/NI201700019A/es unknown
- 2017-02-17 MX MX2022001105A patent/MX2022001105A/es unknown
- 2017-02-17 GT GT201700033A patent/GT201700033A/es unknown
- 2017-02-17 CO CONC2017/0001561A patent/CO2017001561A2/es unknown
- 2017-02-17 DO DO2017000046A patent/DOP2017000046A/es unknown
- 2017-03-22 US US15/466,113 patent/US20170198042A1/en not_active Abandoned
- 2017-11-20 US US15/817,691 patent/US10618958B2/en active Active
-
2019
- 2019-01-22 AU AU2019200426A patent/AU2019200426B2/en active Active
- 2019-07-10 CL CL2019001926A patent/CL2019001926A1/es unknown
-
2020
- 2020-05-15 US US16/806,658 patent/US20200270346A1/en active Pending
- 2020-06-11 JP JP2020101881A patent/JP7066777B2/ja active Active
- 2020-08-05 JO JOP/2020/0192A patent/JOP20200192A1/ar unknown
-
2021
- 2021-04-19 AU AU2021202360A patent/AU2021202360A1/en active Pending
-
2022
- 2022-04-27 JP JP2022073522A patent/JP2022105108A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201700033A (es) | Anticuerpos anti tigit | |
ECSP19020740A (es) | Anticuerpos anti-cd27 | |
CO2017004736A2 (es) | Péptidos macrociclicos útiles como inmunomoduladores | |
CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
TWD182297S (zh) | 車輛引擎蓋 | |
TWD180675S (zh) | 車輛引擎蓋 | |
TWD180661S (zh) | 車輛引擎蓋 | |
CL2017000806A1 (es) | Compuestos anti-tnf | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CL2017000053A1 (es) | Anticuerpos de unión a protofibrillas aß | |
BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
CO2017005566A2 (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis | |
AR111715A1 (es) | ANTICUERPOS ANTI-SIRPa | |
AR120118A2 (es) | Anticuerpos anti tigit | |
EA202091619A3 (ru) | Антитела против tigit | |
UA104459U (uk) | Застосування лактопротеїну з сорбітолом як цитопротектора аденогіпофіза при опіковій хворобі |